Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05168163 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Dec 31, 2025 → Jun 30, 2026
See other at-risk trials from Academic and Community Cancer Research United

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 31, 2025 to Jun 30, 2026v18
  2. Primary completion date: Dec 31, 2024 to Dec 31, 2025
    • Site details revised at 3 of 16 sites
    v17
  3. Site details revised at 4 of 16 sitesv16
  4. Site details revised at 1 of 16 sitesv15
  5. Site details revised at 1 of 16 sitesv14
Show 12 earlier versionsHide 12 earlier versions
  1. Site contacts updated at 1 of 16 sitesv13
  2. Study sites: 13 to 16v12
  3. Study sites: 12 to 13v11
  4. Site details revised at 2 of 12 sitesv10
  5. Site details revised at 1 of 12 sitesv9
  6. Site contacts updated at 1 of 12 sitesv8
  7. Site details revised at 1 of 12 sitesv7
  8. Site details revised at 2 of 12 sitesv6
  9. Site details revised at 1 of 12 sitesv5
  10. Collaborators: 1 to 2v4
  11. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 31, 2022 to May 27, 2022
    • Site details revised at 12 of 12 sites
    v3
  12. Start date: Dec 31, 2021 to May 31, 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic), for which the patient has received treatment in the past (previously treated). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib and lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab with cabozantinib or lenvatinib may kill more tumor cells in patients with liver cancer.
Trial Details
NCT Number NCT05168163
Lead Sponsor Academic and Community Cancer Research United
Collaborators: National Cancer Institute (NCI), Genentech, Inc.
Conditions
(from sponsor)		 Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8 +1 more
Related terms Carcinoma, Hepatocellular
Enrollment 122 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov